Results 121 to 130 of about 51,637 (256)

The Creation of a Weight of Evidence Scoring Database for Risk Factors for Adverse Impacts to Birth Outcomes Using Expert Elicitation

Birth Defects Research, Volume 118, Issue 1, January 2026.
ABSTRACT Background Adverse birth outcomes are important public health measures and account for a substantial public health burden. There is considerable diversity of these health endpoints, as well as in the many factors suspected or recognized to increase their risk.
Paul J. Villeneuve, Ann Aschengrau, Michelle L. Bell, Yang Cao, Mark Elwood, Guy Eslick, Shelley Harris, Leeka Kheifets, Babak Khoshnood, Robert Norman, Nelson Pace, Johan Reutfors, Jeremy M. Schraw, Jose R. Suarez‐Lopez, Gunnar Toft, R. Douglas Wilson, Christopher R. Kirman, Tyler Carneal, Sean M. Hays   +18 more
wiley   +1 more source

Immune Checkpoint Inhibitor‐Associated Myocarditis With Myositis/Myasthenia Gravis Overlap Syndrome: Two Case Reports Highlighting Early Onset, Diagnostic Uncertainty, and Management Considerations

Clinical Case Reports, Volume 14, Issue 1, January 2026.
Custom illustration created by the author in collaboration with the Mayo Clinic Digital Media Department. ABSTRACT Immune checkpoint‐inhibitors (ICIs) have revolutionized and significantly improved cancer care through remarkable efficacy, but significant adverse effects have been observed.
Artur Schneider, Nikita Jhawar, Deepica Reddy, Razvan Chirila   +3 more
wiley   +1 more source

Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states

, 2015
Ted M. Burns, Donald B. Sanders, Henry J. Kaminski, Gil I. Wolfe, Pushpa Narayanaswami, Jürgen Venitz   +5 more
openalex   +2 more sources

Multidimensional Assessment of Neurological Adverse Reactions Related to PD‐1 Inhibitors: A Real‐World Pharmacovigilance Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
This pharmacovigilance study systematically analyzed PD‐1 inhibitor–associated neurological adverse events using FAERS data from 2014 to 2024. Central nervous system toxicities, including encephalitis and brainstem encephalitis, were most prominent. Older age, female sex, specific cancer types, and combination therapies increased the risk, with most ...
Xiaofeng Hu, Xiaoli Wang, Bufu Tang, Dehuan Zhang, Rongbing Cai, Hui Jiang, Yaling Lin, Yiheng Song, Yiou Wang, Hairuo Huang, Dandan Guo, Xubin Sun, Hongjie Fan   +12 more
wiley   +1 more source

Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
A multicenter adult gMG cohort from five tertiary centers in China (N = 118) received efgartigimod 10 mg/kg IV weekly × 4. Early minimal symptom expression (MSE) response was defined as MG‐ADL ≤ 1 sustained ≥ 4 weeks and assessed within 4 weeks. A three‐factor nomogram (bulbar MG‐ADL subscore, FVC% predicted, serum IgG) was developed in the derivation ...
Yufang Yang, Tao Liang, Mingming Zhao, Hongxia Yang, Zhilan Zhao, Lu Yu, Linlin Yan, Siyuan Li, Peng Zhang, Guoyan Qi, Jian Yin, Zucai Xu, Zhong Luo   +12 more
wiley   +1 more source

Effects of alternate-day prednisone therapy on respiratory function in myasthenia gravis. [PDF]

, 1976
Harold H. Newball, Sami A. Brahim
openalex   +1 more source

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
Immune checkpoint inhibitors are associated with rare but severe paraneoplastic syndromes, particularly in lung cancer patients. PS onset shows a bimodal pattern, with increased severity seen in combination therapies like durvalumab plus tremelimumab.
Bufu Tang, Xin Song, Yiting Sun, Juncheng Wan, Wenlu Hu, Yifei Ma, Yihang Lin, Jian Zhang, Yiou Wang, Hongyang Feng, Peng Luo, Dandan Guo, Xudong Qu   +12 more
wiley   +1 more source

Development of Upper Extremity Deep Vein Thrombosis in a Patient With Seronegative Myasthenia Gravis: A Case Report and Review of Literature [PDF]

N. Cohen, Andrew C. Cook, Ravish Narvel
openalex   +1 more source

Myasthenia Gravis [PDF]

Postgraduate Medical Journal, 1965
openaire   +2 more sources

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 33-45, January 2026.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source